As of Nov 18, 2026, 2 of 2 active firms rate ADIL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ADIL EPS & revenue forecast
EPS · NEXT QUARTER
$-2.59
Range $-5.00 – $-0.18 · 2 analysts · -77% YoY
Next period, 2 analysts expect Adial Pharmaceuticals Inc to earn $-2.59 a share (range $-5.00 – $-0.18), versus $-11.48 a year earlier. Full-year consensus is $-1.05, growing to $-7.45 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Adial Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ADIL.
#1
Jason McCarthy
Maxim Group · Rank #567
Buy
$8.00+110.0% to target
Overall win rate
30%
+ Follow
#2
James Molloy
Alliance Global Partners · Rank #587
Buy
$11.00+188.7% to target
Overall win rate
25%
+ Follow
#3
KR
Kumaraguru Raja
Brookline Capital Markets
Buy
$50.00+1212.3% to target
Coverage
—
+ Follow
#4
Elemer Piros
Lucid Capital
Buy
$6.00+57.5% to target
Coverage
—
+ Follow
#5
EP
Elemer Piros
LUCID CAPITAL MARKETS
Buy
$6.00+57.5% to target
Coverage
—
+ Follow
ADIL stock forecast FAQ
What is ADIL's average 12-month price target?+
The 2 active firms with a live target average $8.50 for Adial Pharmaceuticals Inc over the next 12 months, ranging from a $11.00 high to a $6.00 low, as of Nov 18, 2026.
Is ADIL stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 18, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ADIL?+
The Street-high target is $11.00 (Alliance Global Partners), and the Street-low is $6.00 (LUCID CAPITAL MARKETS). The average of all 2 active-firm targets is $8.50.
How many active Wall Street firms cover ADIL?+
2 active firms have a recognized rating on Adial Pharmaceuticals Inc as of Nov 18, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ADIL?+
Among analysts who currently cover ADIL, Jason McCarthy of Maxim Group has the strongest overall Quantellect track record (Rank #567). Their current call is Buy with a $8.00 target.
What is Adial Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-2.59 per share (range $-5.00 – $-0.18) across 2 analysts. Full-year EPS is projected at $-1.05, rising to $-7.45 the following year.
How much revenue is Adial Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ADIL lately?+
As of Nov 18, 2026, 2 of 2 active firms rate ADIL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ADIL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.